Iron is one of the most important macroelements in the body, which takes part in oxidation-reduction processes, and bioenergetics, and is a part of a number of enzymes. Iron deficiency is associated with food, pregnancy, fetal development, and some diseases. First of all, iron deficiency is established in iron-deficiency anemia, in addition to violations of biochemical indicators, immunological shifts and changes in the activity of vital organs and systems. The purpose of the study was to analyze the properties of iron and its preparations and their effects on the body. Materials and methods. On the topic of the study, a search and analysis of scientific literature was conducted in such databases as PubMed, Google Scholar, Scopus. Results and discussion. Iron reserves in the body are 3–6 g, the daily requirement is 20–30 mg. The need for iron increases in diseases with an increase in cardiac output, an increase in temperature, which requires taking drugs for oral and parenteral administration. In addition, if it is necessary to replenish iron reserves, it is recommended to take extracts from plants that contain it, such as common apricot (fruit pulp), blueberry fruits, beet roots, and common peach fruits. At the same time, it should be noted that iron can be in the oxidizing form of Fe2+ and the reduced form of Fe3+. It was determined that changes in iron metabolism and transport occur in pregnant women, which, in turn, is associated with changes in endothelial protective function. In modern methodological recommendations for the treatment of chronic heart failure, iron preparations are also included in the list of mandatory drugs, because in this condition, in addition to iron deficiency, disorders of the functions of the cardiovascular system have been found. A decrease in iron content has also been determined in various hypoxic conditions. Next they showed changes in iron metabolism in infectious diseases, such as COVID-19, tuberculosis, and HIV infection. In recent years, changes in iron content in neurodegenerative diseases have been noticed. Today, there are oral and parenteral iron preparations, but research is underway to create iron preparations that may have a more targeted effect and less toxicity. Conclusion. The current state of iron research in the functioning of vital organs and the occurrence of diseases presents scientists and clinicians with the task of involving new experimental and clinical methods to expand the understanding of the role of iron in pathobiochemical mechanisms, in pathological conditions, as well as the search for new approaches to treatment

Keywords: iron, transport mechanisms, iron-containing enzymes, iron deficiency, cardiovascular, infectious, neurodegenerative diseases

Full text: PDF (Ukr) 267K

1. Zaharova IN, Machneva EB. Korrektsiya defitsita zheleza: istoricheskie and sovremennyie aspektii [Correction of iron deficiency: historical and modern aspects]. Semeynaya meditsina. 2014;1(57):142-5. [Russian]
2. Stepurko T, Semyhina T, Barska Y, Zakhozha V, Kharchenko N. Indeks zdorovia. Ukraine-2018: results of zahalnonatsionalnoho doslidzhennia [Indexes of health. Ukraine-2018: results of global national achievement]. eKMAIR. 2018. [Ukrainian]. Available from: http://ekmair.ukma.edu.ua/handle/123456789/18335
3. Vinogradova OP, Kuznetsova MN, Biryuchkova OA. Antianemic preparations in complex treatment of inflammatory diseases of small organs. Obstetrics Gynecol. 2015;2:49-52.
4. Gromova OA, Torshin IY, Hadzhidis AK. Analiz mokulekyarnyih mehanizmov vozdeystviya zheleza (II), medi, margantsa v patogeneze zhelezodefitsitnoy anemii [Analysis of the Muculeciar Mechanisms of the Effects of Iron (II), Copper, and Manganese in the Pathogenesis of Iron Deficiency Anemia]. Clin Pharmacol Pharmacoeconomics. 2010;1:1-9. [Russian]
5. Belovol AN, Knyazkova II. Ot metabolyzma zheleza - k voprosam pharmakolohycheskoi korrektsyy eho defytsyta [From iron metabolism to issues of pharmacological correction of its deficiency]. Liki Ukrayini. 2015;4:46–51. [Russian]
6. Rumyantsev AG, Zaharova IN, Chernov VM, Tarasova IS, Zaplatnikov AL, Korovina NA, et al. Rasprostranennost zhelezodefitsitnyih sostoyaniy i faktorii, na nee vliyayuschie [The prevalence of iron deficiency states and trading posts that affect it]. Meditsinskiy sovet. 2015;6:62-6. [Russian]
7. Baird-Gunning J, Bromley J. Correcting iron deficiency. Australian Prescriber. 2016;39(6):193-9. PMID: 27990046. PMCID: PMC5155066. https://doi.org/10.18773/austprescr.2016.069
8. Camaschella C. Iron-deficiency anemia. New Engl J Med. 2015;372(19):1832-43. PMID: 25946282. https://doi.org/10.1056/NEJMra1401038
9. Zaporozhan VN, Ancheva IA. Pharmacocorrection of endothelial dysfunction, occurred during comorbid deficiency anemia as a means of preventing complications of pregnancy and childbirth. Health Women. 2015;98(2):71-4. https://doi.org/10.15574/HW.2015.98.71
10. Venkataramani V. Iron homeostasis and metabolism: Two sides of a coin. Adv Exp Med Biol. 2021;1301:25-40. PMID: 34370286. https://doi.org/10.1007/978-3-030-62026-4_3
11. Magomedova AP, Lomova NA, Karapetyan TE, Amiraslanov EY. Latentnyiy defitsit zheleza and zhelezodefitsitnaya anemia beremennyih: posledstviya dlya materi i ploda, vozmozhnyie puti resheniya [Latent iron deficiency and iron deficiency anemia in pregnancy: consequences for the mother and fetus, possible solutions]. Meditsinskiy sovet. 2021;4:170-3. [Russian]. https://doi.org/10.21518/2079-701X-2021-4-170-173
12. Gaillard R, Steegers EAP, Tiemeier H, Hofman A, Jaddoe VWV. Placental vascular dysfunction, fetal and childhood growth, and cardiovascular development. Circulation. 2013;128(20):2202-10. PMID: 24135069. https://doi.org/10.1161/CIRCULATIONAHA.113.003881
13. Arzoo S, Yousof S, Rahman J, Chowdhury S. Iron deficiency anemia in pregnancy: Intravenous iron sucrose versus oral iron sulfate. Bangladesh J Obstetr Gynaecol. 2020;33(1):40-4. https://doi.org/10.3329/bjog.v33i1.43541
14. Dalal M, Goyal R, Nanda S, Dahiya P, Dahiya K, Madan S. Oral versus intravenous iron for treatment of iron deficiency anemia in pregnancy: A randomized controlled trial. Indian J Public Health Res Development. 2018;9(6):4-6. https://doi.org/10.5958/0976-5506.2018.00513.2
15. Rogozińska E, Daru J, Nicolaides M, Amezcua-Prieto C, Robinson S, Wang R, et al. Iron preparations for women of reproductive age with iron deficiency anemia in pregnancy (Frida): A systematic review and network meta-analysis. Lancet Haematol. 2021;8(7):503-12. https://doi.org/10.1016/S2352-3026(21)00137-X
16. Gopchuk OM. Iron deficiency anemia. Women's Health. 2019;9(145):32-7. https://doi.org/10.15574/HW.2019.145.32
17. Ganz T. Anemia of inflammation. New Engl J Med. 2019;381(12):1148-57. PMID: 31532961. https://doi.org/10.1056/NEJMra1804281
18. Liu Z, Sun R, Li J, Cheng W, Li L. Relations of anemia with the all-cause mortality and cardiovascular mortality in the general population: A meta-analysis. Am J Med Sci. 2019;358(3):191-9. PMID: 31331612. https://doi.org/10.1016/j.amjms.2019.05.016
19. Voronkov LG, Gorbachova VV, Liashenko AV, Gavrilenko TI, Mkhitaryan LS, Yakushko LV, et al. Clinical and instrumental characteristics of patients with chronic heart failure and reduced left ventricular ejection fraction without anemia, depending on the presence of iron deficiency. Ukr J Cardiol. 2018;(6):101-8. [Ukrainian]. https://doi.org/10.31928/1608-635X-2018.6.101108
20. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2014;36(11):657-68. PMID: 25176939. PMCID: PMC4359359. https://doi.org/10.1093/eurheartj/ehu385
21. Hörl WH. Anemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol. 2013;9(5):291-301. PMID: 23438972. https://doi.org/10.1038/nrneph.2013.21
22. Nikitin OD. Efektyvnist ta bezpeka zastosuvannia preparatu Sufer® v korektsii anemii u patsiientiv iz khronichnoiu nyrkovoiu destatnistiu [The effectiveness and safety of Sufer® in the correction of anemia in patients with chronic kidney disease]. Ukr Med Chasopys. 2015;1:49-51. [Ukrainian]
23. Ryndina NH, Kravchun PH, Mishyna MM. Pokaznyky ferokinezu yak prohnostychni markersy yakosti zhyttia anemichnykh khvorykh na khronichnu sertsevu dostastatnist, poiednanu z khronichnoiu khvoroboiu nyrok, ta yikh dynamika pid vlividom terapevtychnoi korektsii [Indicators of ferrokinesis as prognostic markers of the quality of life of anemic patients with chronic heart failure combined with chronic kidney disease and their dynamics under the influence of therapeutic correction]. Zdobutky klinichnoi i eksperimentalnoi medytsyny. 2013;2:152-4. [Ukrainian]
24. Popovich MY. Iron deficiency anemia in Zakarpattya High mountain region: Relevance, diagnosis, and comprehensive treatment. Hematology Transfusiology Eastern Europe. 2020;(3):372-82. https://doi.org/10.34883/PI.2020.6.3.023
25. Musina NN, Saprina TV, Prohorenko TS, Zima AP, Prokonich DA. Osobennosti pokazateley vospaleniya, ferrokinetiki i struktury sindroma anemii u bol'nykh sakharnym diabetom [Features of parameters of inflammation, ferrokinetics and structure of anemia syndrome in patients with diabetes]. Conference Proceedings. 2021;2021:72-80. [Russian]. https://doi.org/10.14341/Conf22-25.09.21-378
26. Taneri PE, Alejandro Gómez-Ochoa S, Llanaj E, Francis Raguindin P, Rojas LZ, Wyssmann BM, et al. Anemia and iron metabolism in COVID-19: A systematic review and meta-analysis. Eur J Epidemiol. 2020;35(8):763-73. https://doi.org/10.1101/2020.06.04.20122267
27. Borodulina EA, Yakovleva EV. [Iron metabolism and indicators reflecting its changes in pulmonary tuberculosis (literature review)]. Clin Lab Diagn. 2020;65(2):149-54. [Russian]. PMID: 32163688. https://doi.org/10.18821/0869-2084-2020-65-3-149-154
28. Shahandeh A, Bui BV, Finkelstein DI, Nguyen CT. Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina. J Neurosci Res. 2020;98(10):1889-904. PMID: 32643793. https://doi.org/10.1002/jnr.24685
29. Shu W, Dunaief J. Potential treatment of retinal diseases with Iron Chelators. Pharmaceuticals. 2018;11(4):112. PMID: 30360383. PMCID: PMC6316536. https://doi.org/10.3390/ph11040112
30. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in Brain Aging and Neurodegenerative Disorders. Lancet Neurol. 2014;13(10):1045-60. https://doi.org/10.1016/S1474-4422(14)70117-6
31. Kostromitska IO, Misiurova AV, Propisnova VV. Kliniko-farmatsevtychnyi analiz Fe-vmisnykh preparativ, provedenyi na bazi apteky "Fetida" m. Kharkiv [Clinical and pharmaceutical analysis of Fe-containing drugs, carried out on the basis of the "Fetida" pharmacy, Kharkiv]. Pharmacoeconomics in Ukraine: status and prospects. 2021 May21;1:65-6. [Ukrainian]
32. Nikravesh N, Borchard G, Hofmann H, Philipp E, Flühmann B, Wick P. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice. Nanomedicine. 2020;26:102178. PMID: 32145382. https://doi.org/10.1016/j.nano.2020.102178